Table 3.
Lipid modifying treatment of study population
| Overall N = 712 | LDL-C goal attainment N = 71 | No LDL-C goal attainment N = 641 | p-value | |
|---|---|---|---|---|
|
Monotherapy |
476 (66.9) |
43 (60.6) |
433 (67.6) |
0.2 |
| Statin |
465 (65.3) |
43 (60.6) |
422 (65.8) |
0.4 |
| Fibrate |
4 (0.6) |
0 (0) |
4 (0.6) |
1.0 |
| Ezetimibe |
7 (1.0) |
0 (0) |
8 (1.2) |
1.0 |
|
Combination therapy |
236 (33.1) |
28 (39.4) |
208 (32.4) |
0.2 |
| Statin + Ezetimibe |
182 (25.6) |
22 (31.0) |
160 (25.0) |
0.3 |
| Statin + Ezetimibe + n3 fatty acids |
24 (3.4) |
2 (2.8) |
22 (3.4) |
1.0 |
| Statin + n3 fatty acids |
24 (3.4) |
2 (2.8) |
22 (3.4) |
1.0 |
| Other |
6 (0.8) |
2 (2.8) |
4 (0.6) |
0.1 |
|
% LDL-C reduction efficacy |
|
|
|
0.5 |
| low |
42 (5.9) |
4 (5.6) |
38 (5.9) |
|
| moderate |
486 (68.3) |
45 (63.4) |
441 (68.8) |
|
| high |
160 (22.5) |
18 (25.4) |
142 (22.2) |
|
| very high | 24 (3.4) | 4 (5.6) | 20 (3.1) |
Data are expressed as n (%).